Bryxta 400mg Injection
Rx RequiredSalt Composition: Bevacizumab
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
1 Vial
About The Product
- Advanced non-small-cell lung cancer
- Liver Cancer—Hepatocellular carcinoma
- Persistent, recurrent, or metastatic breast cancer
- Metastatic cervical cancer
- Advanced kidney cancer
- Metastatic colorectal cancer
- Glioblastoma multiforme (brain cancer)
- Ovary, cervical, fallopian tube, or primary peritoneal cancer.
Bevacizumab is an active component of the anticancer medicine Bryxta 400mg Injection. This medication was developed to prevent tumors from growing. It can be administered in combination with other chemotherapeutic medications to treat colorectal, lung, kidney, brain, cervical, and metastatic breast cancer. Further, it is used to treat primary peritoneal cancer, fallopian tube cancer, and ovarian cancer. Children under the age of eighteen and teens are not advised to use Bryxta 400mg Injection. Bryxta (Bevacizumab) is available in the form of injections with strengths of 100mg and 400mg.
Uses
The following conditions are approved for injection treatment with Bryxta 400mg:
- Advanced non-small-cell lung cancer
- Liver Cancer- Hepatocellular carcinoma
- Persistent, recurrent, or metastatic breast cancer
- Metastatic cervical cancer
- Advanced kidney cancer
- Metastatic colorectal cancer
- Glioblastoma multiforme (brain cancer)
- Ovary, cervical, fallopian tube, or primary peritoneal cancer.
Side Effects
Bryxta 400mg Injection may cause some serious and unwanted side effects. This requires immediate medical attention; otherwise, it can also lead to a higher risk. Do not forget to discuss the risks and benefits of this medication with your doctor.
- Bleeding gums
- Chest pain
- Sore throat
- Fever
- Dizziness
- Irregular heartbeat
- Loss of appetite
- Body pain
- Runny nose
- Vomiting
- Diarrhea
- Unusual bleeding
- High blood pressure
Dosage and Administration
- Bryxta 400mg Injection will be given intravenously by your doctor or nurse.
- After the dilution, the infusion must be injected immediately.
- The 400 mg injection of bevacizumab according to recommendations by your physician.
- Make sure to take this injection in accordance with your dose regimen and avoid mishandling this medication.
- Your doctor can provide emergency medical care in the event of an overdose.
Mechanism of action
- Bryxta 400mg is a a recombinant humanized monoclonal antibody is for treating a variety of advanced malignancies as a targeted therapy.
- It works by attaching itself specifically to the protein known as vascular endothelial growth factor A (VEGF-A), which is found in the body's blood and lymph arteries.
- It prohibits VEGF-A from binding with its receptors. This additionally blocks of blood vessels which supply the tumor with nutrients and oxygen. As a result, it slows the rate at which cancer progresses.
Safety Advice
While undergoing therapy with Bryxta 400mg Injection, ask your doctor if it's safe for you to drink alcohol.
If you are pregnant or want to become pregnant, let your doctor know before beginning Bryxta 400mg Injection medication.
Bryxta 400mg Injection may affect your child's growth; it is recommended to avoid breastfeeding for at least six months following your treatment.
Avoid driving or using machinery while you are on your treatment with Bryxta 400mg Injection as it is related to cause dizziness or sleepiness.
Do not take Bevacizumab 400mg Injection without a doctor's consultation in case of kidney problems.
To prevent any severe adverse effects, let your doctor know if you have liver illness before beginning Bryxta 400mg Injection.
Before beginning Bryxta 400mg injection medication, let your doctor know if you have any lung issues.
Missed Doses
- Bevacizumab 400mg Injection is given by your doctor or nurse.
- If you miss an appointment for a scheduled dose of this medicine, contact your doctor immediately.
FAQs
This infusion is used to treat a certain type of brain tumor and cancer of the kidney, colorectal, lung, ovarian, etc.
References
- Vaidyanathan, A., Vana, P., Joshi, N., Sourav, B., Bhargava, P., John, G., Ramaswamy, A., & Ostwal, V. (2025). Real-world evidence for comparative outcomes between innovator and biosimilar bevacizumab in advanced colorectal cancers. South Asian Journal of Cancer, 13(4), 296–299. https://doi.org/10.1055/s-0045-1804535
- Kasliwal, R. S., Reddy, P., Maharaj, N., Shah, H., Nayak, M., Dhoot, D., & Jain, S. (2023). Comparison of efficacy and safety of a bevacizumab biosimilar, in combination with chemotherapies, in nonresectable metastatic colorectal cancer and advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, Phase III study. South Asian Journal of Cancer, 13(1), 66–76. https://doi.org/10.1055/s-0043-1774403
- Sinha, S. D., Biswas, G.,Bheemareddy, B. R., Dubashi, B., Rangwala, R., Pandey, A. K., & Venkitaraman, R. (2023). A real-world study of safety, immunogenicity and efficacy of Bevacizumab in patients with solid malignancies: A Phase IV, post-marketing study in India. Cancer Informatics, 22, 11769351231177277. https://doi.org/10.1177/11769351231177277
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
